Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Progress in clinical research Diabetic retinopathy As a leading cause of vision loss in working-age adults, DR presents a major therapeutic challenge [61, 77]
That's according to new research from the University of British Columbia showing that medications known as GLP-1 agonists - which includes brands like Wegovy, Ozempic, Rybelsus and Saxenda - are associated with an increased risk of serious medical conditions including stomach paralysis, pancreatitis and bowel obstruction
EurekAlert!April 10, 2026
Nooms GLP-1 Companion Receives Major Update to Prepare for New Expected Prescription Drug Use-Related Software (PDURS) Model Noom releases a significant update of its innovative GLP-1 companion to improve medication persistence and adherence while decreasing side effect prevalence and improving lean mass preservation and weight loss outcomes
US$ 29.33
US$ 21.34
US$ 22.37
US$ 29.73
